0.007928
0.000000
0.000000
0.000000
0.007928
0.000000
0.000000
0.000000
0.013253
0.00000
0.00000
0.00000
Petersen, J.
Edman, K.
Edfeldt, F.
Johansson, C.
http://mmcif.pdb.org/dictionaries/ascii/mmcif_pdbx.dic
16
90.00
90.00
90.00
126.143
126.143
75.454
C15 H11 N O
221.254
2-PHENYLQUINOLIN-4-OL
non-polymer
C3 H7 N O2
89.093
y
ALANINE
L-peptide linking
C6 H15 N4 O2 1
175.209
y
ARGININE
L-peptide linking
C4 H8 N2 O3
132.118
y
ASPARAGINE
L-peptide linking
C4 H7 N O4
133.103
y
ASPARTIC ACID
L-peptide linking
C3 H7 N O2 S
121.158
y
CYSTEINE
L-peptide linking
C5 H10 N2 O3
146.144
y
GLUTAMINE
L-peptide linking
C5 H9 N O4
147.129
y
GLUTAMIC ACID
L-peptide linking
C2 H5 N O2
75.067
y
GLYCINE
peptide linking
C6 H10 N3 O2 1
156.162
y
HISTIDINE
L-peptide linking
H2 O
18.015
WATER
non-polymer
C6 H13 N O2
131.173
y
ISOLEUCINE
L-peptide linking
C6 H13 N O2
131.173
y
LEUCINE
L-peptide linking
C6 H15 N2 O2 1
147.195
y
LYSINE
L-peptide linking
C5 H11 N O2 S
149.211
y
METHIONINE
L-peptide linking
C9 H11 N O2
165.189
y
PHENYLALANINE
L-peptide linking
C5 H9 N O2
115.130
y
PROLINE
L-peptide linking
C3 H7 N O3
105.093
y
SERINE
L-peptide linking
C4 H9 N O3
119.119
y
THREONINE
L-peptide linking
C9 H11 N O3
181.189
y
TYROSINE
L-peptide linking
C5 H11 N O2
117.146
y
VALINE
L-peptide linking
UK
Bioorg.Med.Chem.Lett.
BMCLE8
1127
0960-894X
21
777
10.1016/J.BMCL.2010.11.110
21183345
Non-Covalent Inhibitors of Rhinovirus 3C Protease.
2011
1.000000
0.000000
0.000000
0.000000
1.000000
0.000000
0.000000
0.000000
1.000000
0.00000
0.00000
0.00000
100
1
SINGLE WAVELENGTH
M
x-ray
1
1.0
ESRF
SYNCHROTRON
ESRF
20125.793
PICORNAIN 3C
3.4.22.28
1
man
polymer
221.254
2-PHENYLQUINOLIN-4-OL
1
syn
non-polymer
18.015
water
30
nat
water
PROTEASE 3C, P3C, HUMAN RHINOVIRUS 3C PROTEASE
no
no
GSGPEEEFGMSLIKHNSCVITTENGKFTGLGVYDRFVVVPTHADPGKEIQVDGITTKVIDSYDLYNKNGIKLEITVLKLD
RNEKFRDIRRYIPNNEDDYPNCNLALLANQPEPTIINVGDVVSYGNILLSGNQTARMLKYSYPTKSGYCGGVLYKIGQVL
GIHVGGNGRDGFSAMLLRSYFT
GSGPEEEFGMSLIKHNSCVITTENGKFTGLGVYDRFVVVPTHADPGKEIQVDGITTKVIDSYDLYNKNGIKLEITVLKLD
RNEKFRDIRRYIPNNEDDYPNCNLALLANQPEPTIINVGDVVSYGNILLSGNQTARMLKYSYPTKSGYCGGVLYKIGQVL
GIHVGGNGRDGFSAMLLRSYFT
A
polypeptide(L)
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
n
sample
169066
HUMAN RHINOVIRUS SP.
562
ESCHERICHIA COLI
3.73
67.01
NONE
repository
Initial release
Version format compliance
Version format compliance
1
0
2011-04-27
1
1
2011-05-08
1
2
2011-07-13
FAB FRAGMENT (ANTIBODY 8F5) COMPLEXED WITH PEPTIDE FROMHUMAN RHINOVIRUS (SEROTYPE 2) VIRAL CAPSID PROTEIN VP2(RESIDUES 156 - 170)
TYPE 2 RHINOVIRUS 3C PROTEASE WITH AG7088 INHIBITOR
2A CYSTEINE PROTEINASE FROM HUMAN RHINOVIRUS 2
HUMAN RHINOVIRUS 2 BOUND TO A FRAGMENT OF ITS CELLULARRECEPTOR PROTEIN
HUMAN RHINOVIRUS SEROTYPE 2 (HRV2)
SHEET
DETERMINATION METHOD: DSSP
THE SHEETS PRESENTED AS "AB" IN EACH CHAIN ON SHEET RECORDS
BELOW IS ACTUALLY AN 6-STRANDED BARREL THIS IS REPRESENTED BY
A 7-STRANDED SHEET IN WHICH THE FIRST AND LAST STRANDS
ARE IDENTICAL.
PDBE
Y
PDBE
2010-11-16
REL
7L4
2-PHENYLQUINOLIN-4-OL
HOH
water
7L4
1181
2
7L4
7L4
1181
A
HOH
2001
3
HOH
HOH
2001
A
HOH
2002
3
HOH
HOH
2002
A
HOH
2003
3
HOH
HOH
2003
A
HOH
2004
3
HOH
HOH
2004
A
HOH
2005
3
HOH
HOH
2005
A
HOH
2006
3
HOH
HOH
2006
A
HOH
2007
3
HOH
HOH
2007
A
HOH
2008
3
HOH
HOH
2008
A
HOH
2009
3
HOH
HOH
2009
A
HOH
2010
3
HOH
HOH
2010
A
HOH
2011
3
HOH
HOH
2011
A
HOH
2012
3
HOH
HOH
2012
A
HOH
2013
3
HOH
HOH
2013
A
HOH
2014
3
HOH
HOH
2014
A
HOH
2015
3
HOH
HOH
2015
A
HOH
2016
3
HOH
HOH
2016
A
HOH
2017
3
HOH
HOH
2017
A
HOH
2018
3
HOH
HOH
2018
A
HOH
2019
3
HOH
HOH
2019
A
HOH
2020
3
HOH
HOH
2020
A
HOH
2021
3
HOH
HOH
2021
A
HOH
2022
3
HOH
HOH
2022
A
HOH
2023
3
HOH
HOH
2023
A
HOH
2024
3
HOH
HOH
2024
A
HOH
2025
3
HOH
HOH
2025
A
HOH
2026
3
HOH
HOH
2026
A
HOH
2027
3
HOH
HOH
2027
A
HOH
2028
3
HOH
HOH
2028
A
HOH
2029
3
HOH
HOH
2029
A
HOH
2030
3
HOH
HOH
2030
A
GLY
-1
n
1
GLY
-1
A
SER
0
n
2
SER
0
A
GLY
1
n
3
GLY
1
A
PRO
2
n
4
PRO
2
A
GLU
3
n
5
GLU
3
A
GLU
4
n
6
GLU
4
A
GLU
5
n
7
GLU
5
A
PHE
6
n
8
PHE
6
A
GLY
7
n
9
GLY
7
A
MET
8
n
10
MET
8
A
SER
9
n
11
SER
9
A
LEU
10
n
12
LEU
10
A
ILE
11
n
13
ILE
11
A
LYS
12
n
14
LYS
12
A
HIS
13
n
15
HIS
13
A
ASN
14
n
16
ASN
14
A
SER
15
n
17
SER
15
A
CYS
16
n
18
CYS
16
A
VAL
17
n
19
VAL
17
A
ILE
18
n
20
ILE
18
A
THR
19
n
21
THR
19
A
THR
20
n
22
THR
20
A
GLU
21
n
23
GLU
21
A
ASN
22
n
24
ASN
22
A
GLY
23
n
25
GLY
23
A
LYS
24
n
26
LYS
24
A
PHE
25
n
27
PHE
25
A
THR
26
n
28
THR
26
A
GLY
27
n
29
GLY
27
A
LEU
28
n
30
LEU
28
A
GLY
29
n
31
GLY
29
A
VAL
30
n
32
VAL
30
A
TYR
31
n
33
TYR
31
A
ASP
32
n
34
ASP
32
A
ARG
33
n
35
ARG
33
A
PHE
34
n
36
PHE
34
A
VAL
35
n
37
VAL
35
A
VAL
36
n
38
VAL
36
A
VAL
37
n
39
VAL
37
A
PRO
38
n
40
PRO
38
A
THR
39
n
41
THR
39
A
HIS
40
n
42
HIS
40
A
ALA
41
n
43
ALA
41
A
ASP
42
n
44
ASP
42
A
PRO
43
n
45
PRO
43
A
GLY
44
n
46
GLY
44
A
LYS
45
n
47
LYS
45
A
GLU
46
n
48
GLU
46
A
ILE
47
n
49
ILE
47
A
GLN
48
n
50
GLN
48
A
VAL
49
n
51
VAL
49
A
ASP
50
n
52
ASP
50
A
GLY
51
n
53
GLY
51
A
ILE
52
n
54
ILE
52
A
THR
53
n
55
THR
53
A
THR
54
n
56
THR
54
A
LYS
55
n
57
LYS
55
A
VAL
56
n
58
VAL
56
A
ILE
57
n
59
ILE
57
A
ASP
58
n
60
ASP
58
A
SER
59
n
61
SER
59
A
TYR
60
n
62
TYR
60
A
ASP
61
n
63
ASP
61
A
LEU
62
n
64
LEU
62
A
TYR
63
n
65
TYR
63
A
ASN
64
n
66
ASN
64
A
LYS
65
n
67
LYS
65
A
ASN
66
n
68
ASN
66
A
GLY
67
n
69
GLY
67
A
ILE
68
n
70
ILE
68
A
LYS
69
n
71
LYS
69
A
LEU
70
n
72
LEU
70
A
GLU
71
n
73
GLU
71
A
ILE
72
n
74
ILE
72
A
THR
73
n
75
THR
73
A
VAL
74
n
76
VAL
74
A
LEU
75
n
77
LEU
75
A
LYS
76
n
78
LYS
76
A
LEU
77
n
79
LEU
77
A
ASP
78
n
80
ASP
78
A
ARG
79
n
81
ARG
79
A
ASN
80
n
82
ASN
80
A
GLU
81
n
83
GLU
81
A
LYS
82
n
84
LYS
82
A
PHE
83
n
85
PHE
83
A
ARG
84
n
86
ARG
84
A
ASP
85
n
87
ASP
85
A
ILE
86
n
88
ILE
86
A
ARG
87
n
89
ARG
87
A
ARG
88
n
90
ARG
88
A
TYR
89
n
91
TYR
89
A
ILE
90
n
92
ILE
90
A
PRO
91
n
93
PRO
91
A
ASN
92
n
94
ASN
92
A
ASN
93
n
95
ASN
93
A
GLU
94
n
96
GLU
94
A
ASP
95
n
97
ASP
95
A
ASP
96
n
98
ASP
96
A
TYR
97
n
99
TYR
97
A
PRO
98
n
100
PRO
98
A
ASN
99
n
101
ASN
99
A
CYS
100
n
102
CYS
100
A
ASN
101
n
103
ASN
101
A
LEU
102
n
104
LEU
102
A
ALA
103
n
105
ALA
103
A
LEU
104
n
106
LEU
104
A
LEU
105
n
107
LEU
105
A
ALA
106
n
108
ALA
106
A
ASN
107
n
109
ASN
107
A
GLN
108
n
110
GLN
108
A
PRO
109
n
111
PRO
109
A
GLU
110
n
112
GLU
110
A
PRO
111
n
113
PRO
111
A
THR
112
n
114
THR
112
A
ILE
113
n
115
ILE
113
A
ILE
114
n
116
ILE
114
A
ASN
115
n
117
ASN
115
A
VAL
116
n
118
VAL
116
A
GLY
117
n
119
GLY
117
A
ASP
118
n
120
ASP
118
A
VAL
119
n
121
VAL
119
A
VAL
120
n
122
VAL
120
A
SER
121
n
123
SER
121
A
TYR
122
n
124
TYR
122
A
GLY
123
n
125
GLY
123
A
ASN
124
n
126
ASN
124
A
ILE
125
n
127
ILE
125
A
LEU
126
n
128
LEU
126
A
LEU
127
n
129
LEU
127
A
SER
128
n
130
SER
128
A
GLY
129
n
131
GLY
129
A
ASN
130
n
132
ASN
130
A
GLN
131
n
133
GLN
131
A
THR
132
n
134
THR
132
A
ALA
133
n
135
ALA
133
A
ARG
134
n
136
ARG
134
A
MET
135
n
137
MET
135
A
LEU
136
n
138
LEU
136
A
LYS
137
n
139
LYS
137
A
TYR
138
n
140
TYR
138
A
SER
139
n
141
SER
139
A
TYR
140
n
142
TYR
140
A
PRO
141
n
143
PRO
141
A
THR
142
n
144
THR
142
A
LYS
143
n
145
LYS
143
A
SER
144
n
146
SER
144
A
GLY
145
n
147
GLY
145
A
TYR
146
n
148
TYR
146
A
CYS
147
n
149
CYS
147
A
GLY
148
n
150
GLY
148
A
GLY
149
n
151
GLY
149
A
VAL
150
n
152
VAL
150
A
LEU
151
n
153
LEU
151
A
TYR
152
n
154
TYR
152
A
LYS
153
n
155
LYS
153
A
ILE
154
n
156
ILE
154
A
GLY
155
n
157
GLY
155
A
GLN
156
n
158
GLN
156
A
VAL
157
n
159
VAL
157
A
LEU
158
n
160
LEU
158
A
GLY
159
n
161
GLY
159
A
ILE
160
n
162
ILE
160
A
HIS
161
n
163
HIS
161
A
VAL
162
n
164
VAL
162
A
GLY
163
n
165
GLY
163
A
GLY
164
n
166
GLY
164
A
ASN
165
n
167
ASN
165
A
GLY
166
n
168
GLY
166
A
ARG
167
n
169
ARG
167
A
ASP
168
n
170
ASP
168
A
GLY
169
n
171
GLY
169
A
PHE
170
n
172
PHE
170
A
SER
171
n
173
SER
171
A
ALA
172
n
174
ALA
172
A
MET
173
n
175
MET
173
A
LEU
174
n
176
LEU
174
A
LEU
175
n
177
LEU
175
A
ARG
176
n
178
ARG
176
A
SER
177
n
179
SER
177
A
TYR
178
n
180
TYR
178
A
PHE
179
n
181
PHE
179
A
THR
180
n
182
THR
180
A
author_and_software_defined_assembly
PISA
1
monomeric
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
0.0000000000
0.0000000000
0.0000000000
1.0000000000
1_555
x,y,z
identity operation
0.0000000000
0.0000000000
0.0000000000
A
N
THR
54
A
N
THR
56
A
O
ILE
47
A
O
ILE
49
A
N
GLN
48
A
N
GLN
50
A
O
THR
19
A
O
THR
21
A
N
THR
20
A
N
THR
22
A
O
GLY
23
A
O
GLY
25
A
N
VAL
30
A
N
VAL
32
A
O
PHE
34
A
O
PHE
36
A
N
VAL
37
A
N
VAL
39
A
O
THR
73
A
O
THR
75
A
N
VAL
74
A
N
VAL
76
A
O
TYR
60
A
O
TYR
62
A
N
LEU
104
A
N
LEU
106
A
O
THR
112
A
O
THR
114
A
N
TYR
122
A
N
TYR
124
A
O
MET
135
A
O
MET
137
A
N
TYR
138
A
N
TYR
140
A
O
GLY
169
A
O
GLY
171
A
N
ALA
172
A
N
ALA
174
A
O
ILE
160
A
O
ILE
162
A
N
LEU
158
A
N
LEU
160
A
O
LEU
151
A
O
LEU
153
A
N
TYR
152
A
N
TYR
154
A
O
ASN
101
A
O
ASN
103
1
A
HOH
2006
C
HOH
1
A
ASP
32
50.83
-124.75
1
A
ASP
42
48.68
70.24
1
A
GLU
71
89.89
15.22
1
A
GLU
81
123.89
150.09
1
A
ASN
99
46.42
72.73
1
A
LEU
105
-125.72
-54.89
47.270
-1.43
0.00
0.00
-1.43
0.00
2.86
0.927
0.875
HYDROGENS HAVE BEEN ADDED IN THE RIDING POSITIONS.
0.28850
0.22719
0.22987
2.40
89.09
563
11202
4.8
96.36
7.376
0.175
RANDOM
1
THROUGHOUT
OTHER
0.293
0.257
0.80
0.80
1.40
NONE
MAXIMUM LIKELIHOOD
BABINET MODEL WITH MASK
2.40
89.09
30
1462
17
0
1415
0.014
0.022
1461
2.158
1.987
1978
4.865
5.000
181
35.837
24.545
66
13.303
15.000
246
16.305
15.000
8
0.129
0.200
216
0.007
0.020
1125
0.216
0.200
575
0.315
0.200
992
0.134
0.200
62
0.145
0.200
21
0.112
0.200
5
0.972
1.500
919
1.706
2.000
1450
2.301
3.000
627
3.459
4.500
528
0.458
0.269
2.462
39
748
20
89.94
2.40
45.20
2XYA
12145
0.0
0.10
1
6.60
6.9
99.5
2.40
2.46
1
7.2
refinement
REFMAC
5.2.0019
data reduction
MOSFLM
data scaling
SCALA
PICORNAIN 3C (E.C.3.4.22.28)
Non-covalent inhibtors of rhinovirus 3C protease.
1
N
N
2
N
N
3
N
N
A
GLY
1
A
GLY
3
HELX_P
A
ASN
14
A
ASN
16
1
1
14
A
HIS
40
A
HIS
42
HELX_P
A
ASP
42
A
ASP
44
5
2
3
A
ILE
86
A
ILE
88
HELX_P
A
ILE
90
A
ILE
92
5
3
5
A
LYS
143
A
LYS
145
HELX_P
A
CYS
147
A
CYS
149
5
4
5
A
LEU
175
A
LEU
177
HELX_P
A
PHE
179
A
PHE
181
5
5
5
HYDROLASE
HYDROLASE, CYSTEINE PROTEASE
A
GLY
-1
A
GLY
1
1
A
SER
0
A
SER
2
-2.55
A
SER
0
A
SER
2
1
A
GLY
1
A
GLY
3
3.99
A
ASN
80
A
ASN
82
1
A
GLU
81
A
GLU
83
-3.41
POLG_HRV2
UNP
1
P04936
1508
1687
2XYA
1
180
P04936
A
1
3
182
1
expression tag
GLY
-1
2XYA
A
P04936
UNP
1
1
expression tag
SER
0
2XYA
A
P04936
UNP
2
7
7
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
anti-parallel
A
ILE
52
A
ILE
54
A
LYS
55
A
LYS
57
A
GLU
46
A
GLU
48
A
VAL
49
A
VAL
51
A
SER
15
A
SER
17
A
THR
20
A
THR
22
A
GLY
23
A
GLY
25
A
TYR
31
A
TYR
33
A
PHE
34
A
PHE
36
A
PRO
38
A
PRO
40
A
LYS
69
A
LYS
71
A
LYS
76
A
LYS
78
A
SER
59
A
SER
61
A
TYR
63
A
TYR
65
A
TYR
97
A
TYR
99
A
LEU
104
A
LEU
106
A
THR
112
A
THR
114
A
GLY
123
A
GLY
125
A
ARG
134
A
ARG
136
A
SER
139
A
SER
141
A
ASP
168
A
ASP
170
A
MET
173
A
MET
175
A
GLN
156
A
GLN
158
A
GLY
164
A
GLY
166
A
VAL
150
A
VAL
152
A
LYS
153
A
LYS
155
A
TYR
97
A
TYR
99
A
LEU
104
A
LEU
106
BINDING SITE FOR RESIDUE 7L4 A 1181
Software
13
A
LEU
126
A
LEU
128
13
6_555
A
LEU
127
A
LEU
129
13
6_555
A
SER
128
A
SER
130
13
6_555
A
GLY
129
A
GLY
131
13
6_555
A
THR
132
A
THR
134
13
6_555
A
THR
142
A
THR
144
13
1_555
A
LYS
143
A
LYS
145
13
1_555
A
SER
144
A
SER
146
13
1_555
A
HIS
161
A
HIS
163
13
1_555
A
VAL
162
A
VAL
164
13
1_555
A
GLY
163
A
GLY
165
13
1_555
A
GLY
164
A
GLY
166
13
1_555
A
GLY
166
A
GLY
168
13
1_555
98
I 41 2 2